|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 156.66 USD | +1.59% |
|
-0.28% | +12.95% |
| 08-05 | Sandoz gains on strong biosimilar growth, touts 'golden decade' | RE |
| 08-03 | Correction to Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment Article on July 31 | DJ |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Neutral | Bullish |
| Resistance | 159.9 | 168.62 | 168.62 |
| Spread/Res. | -2.61% | -7.65% | -7.65% |
| Spread/Supp. | +4.12% | +8.94% | +8.16% |
| Support | 149.56 | 142.94 | 143.97 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- NOVN Stock
- NVS Stock
- Charts Novartis AG
Select your edition
All financial news and data tailored to specific country editions
